By Connor Hart
Shares of iSpecimen gained after securing suppliers for the flu-like human metapneumovirus, a virus which causes upper respiratory infections.
The stock rose 22%, to $3.50, in after-hours trading Thursday. Shares ended the regular session 8% higher, at $2.85, putting them down 71% over the last year.
The online marketplace for human biospecimens said the virus has been causing hospitals in China to become overrun, and that it has raised concerns of another public-health pandemic.
"There is currently no vaccine for HMPV, hence the potential need for samples if a company were looking to make this type of breakthrough drug or study the virus," iSpecimen said in a Securities and Exchange Commission filing.
It added the potential demand for a vaccine for the virus highlights the need for reliable access to high-quality specimens.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 16, 2025 18:19 ET (23:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.